

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application No.	10/616,210
				Filing Date:	July 8, 2003
				First Named Inventor	Kopreski
				Group Art Unit	1634
				Examiner Name	F. Lu
Sheet	1	of	2	Attorney Docket No.	00-1313-D

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
<i>u</i>	✓	5,576,178	A	Emanuel et al.	11-1996	_____
↓	✓	5,869,053	A	Stern et al.	2-1999	_____
		6,329,179	B1	Kopreski	12-2001	_____

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. 1	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
<i>u</i>	✓	EP	0 336 582	A	Cancer Research Campaign Technology Ltd.	03-03-1989	_____	
<i>u</i>	✓	WO	97/35589	A	Michael Kopreski	10-02-1997	_____	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
<i>u</i>	✓	SOUTHALL et al. "Immunohistological distribution of 5T4 antigen in normal and malignant tissue, Br. J. Cancer 61:89-95 (1990).	✓
↓	✓	MYERS et al. "Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein." J. Biol. Chem. 269:9319-24 (1994).	✓

Examiner Signature	<i>F. Lu</i>	Date Considered	6/22/2006
--------------------	--------------	-----------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application No.	10/616,210
				Filing Date:	July 8, 2003
				First Named Inventor	Kopreski
				Group Art Unit	1634
				Examiner Name	F. Lu
Sheet	2	of	2	Attorney Docket No.	00-1313-D

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
<i>KL</i>	✓	KOPRESKI et al., "Circulating RNA as a tumor marker," Clinical Chemistry, vol. 47, no. 2, page 362, February 2000.	✓
	✓	KING et al., "Organization of the mouse and human 5T oncofoetal leucine-rich glycoprotein genes and expression in foetal and adult murine tissues", Biochimica et Biophysica Acta. Gene Structure and Expression, Elsevier, Amsterdam, NL, vol. 1445, no. 3, June 9, 1999, pages 257-270.	✓
	✓	PFLEIDERER et al., "Detection of Tumor Cells in Peripheral Blood and Bone Marrow from Ewing Tumour Patients by Rt-PCR." Int. J. Cancer (Red. Oncol.) 1995, 64:135-139.	✓
	✓	KOMEDA et al. "Sensitive Detection of Circulating Hepatocellular Carcinoma Cells in Peripheral Venous Blood," Cancer 75:2214-19. (1999).	✓
	✓	KOPRESKI et al., "Detection of Tumor Messenger RNA in the Serum of Patients with Malignant Melanoma," Clinical Cancer Research, 5:1961-65 (August 1999).	✓
	✓	HASSELMANN et al., "Detection of Tumor-Associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma," Oncology Report, 8:115-118. (2001).	✓
	✓	DATTA et al., "Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction" J. Clin. Oncology 12:475-482 (1994).	✓
	✓	WIECZOREK et al., "Diagnostic and prognostic value of RNA-Proteolipid in sera of patients with malignant disorders following therapy: first clinical evaluation of a novel tumor marker" Cancer Res. 47:6407-12 (1987).	✓

Examiner Signature	<i>F. Lu</i>	Date Considered	6/22/06
-----------------------	--------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231